Definition/General

Introduction:
-Endometrial epithelioid sarcoma is an extremely rare malignant soft tissue tumor occurring in the uterus
-It is characterized by epithelioid morphology and loss of INI1 expression
-It represents less than 0.1% of all uterine sarcomas
-It has an aggressive clinical behavior.
Origin:
-Arises from mesenchymal cells with epithelioid features
-May develop from endometrial stroma
-Uncertain cell of origin
-Associated with SMARCB1 gene inactivation
-Occurs as primary uterine tumor.
Classification:
-Classified as soft tissue sarcoma with epithelioid features
-High-grade malignancy
-Classical and proximal-type variants
-Defined by INI1/SMARCB1 loss
-Aggressive clinical behavior.
Epidemiology:
-Extremely rare in uterine location
-Peak incidence in 2nd-4th decades (classical type)
-Proximal type affects older patients
-Young to middle-aged women affected
-Associated with SMARCB1 mutations.

Clinical Features

Presentation:
-Abnormal uterine bleeding (most common)
-Pelvic mass
-Pelvic pain
-Rapidly growing tumor
-Constitutional symptoms possible
-Advanced disease at presentation.
Symptoms:
-Heavy menstrual bleeding
-Pelvic pressure
-Abdominal pain
-Weight loss
-Fatigue
-Systemic symptoms in advanced cases.
Risk Factors:
-Young age (15-40 years for classical type)
-Genetic predisposition (rhabdoid tumor predisposition syndrome)
-SMARCB1 germline mutations
-Family history of sarcomas.
Screening:
-No specific screening recommendations
-Genetic counseling for familial cases
-High index of suspicion for soft tissue masses
-Imaging studies for staging.

Master Epithelioid Sarcoma Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-Multinodular mass with infiltrative margins
-Gray-white cut surface
-Firm consistency
-Areas of hemorrhage and necrosis
-Pseudocapsule may be present.
Characteristics:
-Size ranges from 2-10 cm
-Irregular margins
-Cut surface shows variegated appearance
-Solid consistency
-Necrotic areas common.
Size Location:
-Variable size at presentation
-Mean size 4-7 cm
-Involves uterine corpus
-May extend to parametrium
-Infiltrative growth pattern.
Multifocality:
-Usually unifocal presentation
-Aggressive local growth
-Lymph node metastases common
-Distant metastases to lung
-Skip lesions possible.

Microscopic Description

Histological Features:
-Epithelioid cells arranged in sheets and nests
-Abundant eosinophilic cytoplasm
-Vesicular nuclei with prominent nucleoli
-Central necrosis in nodules
-High mitotic activity
-Inflammatory infiltrate.
Cellular Characteristics:
-Large epithelioid cells
-Abundant pink cytoplasm
-Vesicular nuclei
-Prominent nucleoli
-Rhabdoid features may be present
-Multinucleated cells.
Architectural Patterns:
-Nodular pattern with central necrosis
-Granuloma-like appearance
-Pseudocarcinomatous pattern
-Solid sheets
-Spindle cell areas (proximal type).
Grading Criteria:
-Considered high-grade by definition
-High mitotic rate (>10/10 HPF)
-Marked nuclear atypia
-Necrosis present
-Aggressive behavior.

Immunohistochemistry

Positive Markers:
-Cytokeratins (focal, variable)
-EMA (focal)
-Vimentin
-CD34 (may be positive)
-FLI-1 (may be positive)
-ERG (variable).
Negative Markers:
-INI1/SMARCB1 (loss of nuclear expression)
-Desmin (negative)
-S-100 (negative)
-Melanoma markers (negative)
-Muscle-specific actin (negative).
Diagnostic Utility:
-INI1/SMARCB1 loss highly specific and diagnostic
-Cytokeratin positivity (focal) may cause diagnostic confusion
-CD34 positivity supportive
-Negative smooth muscle and melanoma markers
-Retained INI1 excludes diagnosis.
Molecular Subtypes:
-SMARCB1 inactivation (gene deletion/mutation)
-SMARCA4 alterations (rare)
-Complex chromosomal alterations
-INI1 protein loss.

Molecular/Genetic

Genetic Mutations:
-SMARCB1 deletions (22q11.23)
-SMARCB1 mutations
-Biallelic inactivation
-Germline mutations in familial cases
-Complex karyotype.
Molecular Markers:
-Loss of INI1/SMARCB1 expression
-Chromosomal instability
-High Ki-67 index
-p16 overexpression
-EZH2 upregulation.
Prognostic Significance:
-Proximal type has worse prognosis than classical
-Size >5 cm adverse prognostic factor
-Age >30 years indicates poor outcome
-Necrosis correlates with aggressive behavior
-Germline mutations may indicate familial syndrome.
Therapeutic Targets:
-EZH2 inhibitors (tazemetostat)
-Immunotherapy (investigational)
-Multi-kinase inhibitors
-Conventional chemotherapy (limited response)
-Radiation therapy (adjuvant).

Differential Diagnosis

Similar Entities:
-Epithelioid malignant peripheral nerve sheath tumor
-Synovial sarcoma
-Carcinoma
-Melanoma
-Epithelioid angiosarcoma.
Distinguishing Features:
-MPNST: S-100 positive, may retain INI1
-Synovial sarcoma: TLE1 positive, INI1 retained
-Carcinoma: Broad cytokeratin positivity
-Epithelioid sarcoma: INI1 loss
-Epithelioid sarcoma: CD34 positive.
Diagnostic Challenges:
-Distinguishing from poorly differentiated carcinoma
-Recognizing epithelioid morphology
-Confirming INI1 loss
-Identifying nodular growth pattern
-INI1 immunostaining essential.
Rare Variants:
-Classical epithelioid sarcoma
-Proximal-type epithelioid sarcoma
-Angiomatoid variant
-Fibroma-like variant.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

[specimen type], measuring [size] cm, firm consistency

Diagnosis

Epithelioid sarcoma of the endometrium

Classification

[Classical/Proximal-type] epithelioid sarcoma

Histological Features

Epithelioid cells in nodular pattern with central necrosis, mitoses: [count]/10 HPF

Morphologic Pattern

Pattern: [nodular/sheet-like/mixed], necrosis: [present/absent]

Immunohistochemistry

INI1/SMARCB1: [lost/retained] (nuclear expression)

Cytokeratins: [focal +/+/-], EMA: [+/-]

CD34: [+/-], Vimentin: [+/-]

Grade

High-grade sarcoma by definition

Final Diagnosis

[Classical/Proximal-type] epithelioid sarcoma with INI1/SMARCB1 loss